Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,477.16
(
-1.74%
)
US TECH 100
23,039.84
(
-2.01%
)
Dow Jones
45,960.11
(
-1.01%
)
Brent Oil
100.67
(
1.92%
)
Bitcoin
68,735.71
(
-3.60%
)
News Focus
News Focus
Post# of 257295
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122815
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: ChikiTiny post# 202522

Monday, 07/11/2016 2:03:38 PM

Monday, July 11, 2016 2:03:38 PM

Post# of 257295

EGRX—Can you elaborate on why MDCO en banc outcome is bullish for Kangio?

The CAFC ruling (upholding MDCO's patents on Angiomax) keeps generic versions of Angiomax off the US market. EGRX's Kangio will therefore have to compete only with MDCO's branded Angiomax when it enters the US market (pending FDA approval).

EGRX was not sued by MDCO wrt Kangio because it was clear that Kangio does not infringe MDCO's patents.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today